Company news

Amgen Inc. news in 2024

Amgen Inc.'s news releases, calls and decks from 2024, newest first.

View company

Amgen announces 2025 first quarter dividend

December 9, 2024

BLINCYTO® (blinatumomab) added to chemotherapy significantly improves survival in newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL)

December 6, 2024

Amgen announces $1 billion manufacturing expansion in North Carolina

December 4, 2024

Amgen to present at citi's 2024 global healthcare conference

December 1, 2024

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

November 28, 2024

Amgen to host webcast to discuss maritide phase 2 results and progress on development program

November 25, 2024

Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a Phase 2 study

November 25, 2024

Amgen announces senior executive research appointment

November 19, 2024

Amgen presents new data across rare inflammatory diseases at acr 2024

November 13, 2024

Amgen provides statement on MariTide Phase 1 data

November 12, 2024

Amgen to present at the 2024 ubs global healthcare conference

November 7, 2024

TEZSPIRE met both co-primary endpoints in Phase 3 trial for chronic rhinosinusitis with nasal polyps

November 6, 2024

Amgen reports third quarter 2024 financial results

October 29, 2024

Amgen announces 2024 fourth quarter dividend

October 24, 2024

Amgen announces webcast of 2024 third quarter financial results

October 23, 2024

Amgen presents positive Phase 3 data for UPLIZNA® (inebilizumab-cdon) in generalized Myasthenia Gravis (gMG) at aanem 2024

October 14, 2024

La La Anthony partners with Amgen to share candid, behind-the-scenes look at how plaque psoriasis affects her life

September 30, 2024

TEPEZZA® (teprotumumab) receives approval in Japan for the treatment of active thyroid eye disease

September 23, 2024

Amgen to host conference call to discuss new topline data in inflammation and rare disease

September 22, 2024

Amgen to present data from multiple early-stage clinical trials at ESMO 2024

September 12, 2024

Amgen presents new data for first-in-class IMDELLTRA™ (tarlatamab-dlle) in small cell lung cancer at wclc 2024

September 8, 2024

Amgen to present at the 2024 wells fargo healthcare conference

August 29, 2024

Amgen to present at the morgan stanley 22nd annual global healthcare conference

August 28, 2024

Otezla® (apremilast) now available in the U.S. for moderate to severe pediatric plaque psoriasis

August 19, 2024

Amgen reports second quarter 2024 financial results

August 5, 2024

Amgen announces 2024 third quarter dividend

August 1, 2024

Amgen announces webcast of 2024 second quarter financial results

July 31, 2024

FDA approves BLINCYTO® (blinatumomab) in CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase

June 13, 2024

Amgen to present innovative rheumatology research at EULAR 2024

June 11, 2024

Amgen to present at goldman sachs 45th annual global healthcare conference

June 4, 2024

Amgen announces positive results for phase 3 registrational trial evaluating uplizna® (inebilizumab-cdon) for treatment of immunoglobulin G4-related disease (IgG4-RD)

June 4, 2024

Amgen to present innovative research from its robust oncology portfolio at ASCO 2024

May 27, 2024

New data presented at ats 2024 show the potential of TEZSPIRE® to help patients living with COPD

May 18, 2024

FDA approves IMDELLTRA™ (tarlatamab-dlle), the first and only t-cell engager therapy for the treatment of extensive-stage small cell lung cancer

May 15, 2024

Amgen to host conference call following ats 2024

May 14, 2024

Amgen reports first quarter 2024 financial results

May 1, 2024

Amgen highlights new COPD, asthma and vasculitis research at ats 2024

April 30, 2024

Amgen announces webcast of 2024 first quarter financial results

April 28, 2024

Amgen to submit teprotumumab marketing authorization application to the European Medicines Agency

April 25, 2024

Amgen to present TEZSPIRE® Phase 2A COPD data at ats 2024

April 15, 2024

Amgen presents new research on Otezla® (Apremilast) at AAD 2024

March 8, 2024

Amgen announces 2024 second quarter dividend

March 5, 2024

Amgen to present at the 44th annual td cowen health care conference

February 28, 2024

Amgen opens state-of-the-art biomanufacturing site in Central Ohio

February 25, 2024

Amgen to host conference call on rare disease

February 18, 2024

Amgen to present at the 34th annual oppenheimer healthcare life sciences conference

February 8, 2024

Amgen reports fourth quarter and full year 2023 financial results

February 5, 2024

Amgen announces webcast of 2023 fourth quarter and full year financial results

January 31, 2024

deCODE genetics: A sequence variant that increases risk of pregnancy loss

January 28, 2024

Amgen to present at the 42nd annual j.p. morgan healthcare conference

January 2, 2024

Calls in 2024

Decks in 2024